To invest in SpectraCure

The aim of SpectraCure’s proprietary and patented treatment system is to eliminate internal cancer tumors and extend the survival of cancer patients. Our technology is based on PDT treatment with IDOSE®.

Our treatment system is suitable for internal solid tumors of various kinds, such as in the prostate and pancreas. The hope is that in the future it will also be possible to treat other cancers such as breast cancer and the head and neck region.

The goal is to reach the European and American markets in about a year through accelerated approval, and also to seek the European counterpart.

READ INFO RIGHT ISSUE 2020 (SWEDISH)

Financial reports


Please find our latest quarterly reports, annual reports etc. Please note: all our reports are in Swedish.

READ MORE

Stock price and analysis


Curious to know more about the latest general analysis?

Check out Analysguiden’s latest analysis by Thomas Nilsson (June 2020)

LATEST ANALYSIS (SWE)

News


Welcome to read SpectraCure’s latest News and Press Releases. If you would like to subscribe to news from us, please sign up through the subscription form below. Please note: most of our information is in Swedish except Press Releases.

PRESS RELEASESINVESTORS LETTER (SWE)NATIVE ADS (SWE)

PRESENTATIONS


June 9 SpectraCure in Småbolagspodden 
June 10 SpectraCure at Småbolagsdagarna
June 22, Live presentation in SpectraCures Facebook group

Technology


PDT treatment with IDOSE® has the potential to be more gentle and not affect healthy tissue as much as other treatments. It has a rapid healing process, which facilitates easier recovery and retained quality of life after the tumor cells have been eliminated.

READ MOREHow it works

Market


The global market for prevention and treatment of prostate cancer is expected to reach $65 billion in 2021, representing an annual growth of 6.6 percent, according to a report from BCC Research Market Forecasting.

The market for Spectracure’s first medical indication, relapse in prostate cancer, is very large. Each year, approximately 190,000 patients become ill in the United States. In Europe, the corresponding figure is about 400,000 patients.

After radiation treatment, about 60,000 of these people suffer from recurrence in prostate cancer, which is initially the target group addressed by SpectraCure.

Subscribe


When submitting a subscription to press releases, quarterly reports and annual reports, your email address will be forwarded to SpectraCures, which handles the mailing service. For more information, see SpectraCures Integritetspolicy.

SOCIAL MEDIA

FOLLOW SPECTRACURES DEVELOPMENT IN ALL CHANNELS